- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- BioSummarAI
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: TEK
Gene name: TEK tyrosine kinase, endothelial
HGNC ID: 11724
Synonyms: TIE2, TIE-2, VMCM1, CD202b
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | CD14 | 1 hits |
| 2 | CD34 | 1 hits |
| 3 | CRP | 1 hits |
| 4 | CTLA4 | 1 hits |
| 5 | CXCR4 | 1 hits |
| 6 | EGF | 1 hits |
| 7 | GOLM1 | 1 hits |
| 8 | GPC3 | 1 hits |
| 9 | HLA-A | 1 hits |
| 10 | HLA-B | 1 hits |
| 11 | IL6 | 1 hits |
| 12 | ITGAM | 1 hits |
| 13 | KDR | 1 hits |
| 14 | PDCD1 | 1 hits |
| 15 | PROM1 | 1 hits |
| 16 | PTPRC | 1 hits |
| 17 | TNMD | 1 hits |
| 18 | VEGFA | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 15069689 | Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. |
| 2 | 15069689 | Moreover, CTLs from mice immunised with the modified construct killed HLA-A*0201 endothelial cells overexpressing Tie-2. |
| 3 | 15069689 | Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. |
| 4 | 15069689 | Moreover, CTLs from mice immunised with the modified construct killed HLA-A*0201 endothelial cells overexpressing Tie-2. |
| 5 | 16408213 | Using computer aided motif predictions for possible HLA class I epitopes, we have identified peptides from Tie-2 that should bind with a range of affinities to HLA-A*0201. |
| 6 | 16408213 | Moreover, the efficiency of immunisation was increased when we linked CD4 epitopes to CD8 epitopes. |
| 7 | 20382859 | Phenotypic EPC populations enumerated by flow cytometry [CD34(+)VEGF receptor (VEGF)R-2(+)CD133(+), CD14(+)VEGFR-2(+)Tie2(+), CD45(-)CD34(+), as a surrogate for late outgrowth EPCs, and CD34(+)CXCR-4(+)], EC-CFUs, and serum cytokine concentrations (high sensitivity C-reactive protein, IL-6, and stromal-derived factor-1) were quantified during the first 7 days. |
| 8 | 20382859 | Vaccination increased circulating leukocyte (9.8 + or - 0.6 vs. 5.1 + or - 0.2 x 10(9) cells/l, P < 0.0001), serum IL-6 [0.95 (0-1.7) vs. 0 (0-0) ng/l, P = 0.016], and VEGF-A [60 (45-94) vs. 43 (21-64) pg/l, P = 0.006] concentrations at 6 h and serum high sensitivity C-reactive protein at 24 h [2.7 (1.4-3.6) vs. 0.4 (0.2-0.8) mg/l, P = 0.037]. |
| 9 | 20382859 | Vaccination caused a 56.7 + or - 7.6% increase in CD14(+) cells at 6 h (P < 0.001) and a 22.4 + or - 6.9% increase in CD34(+) cells at 7 days (P = 0.04). |
| 10 | 22351744 | Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. |
| 11 | 22351744 | However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). |
| 12 | 22351744 | Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. |
| 13 | 22351744 | Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. |
| 14 | 22351744 | Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues. |
| 15 | 24411674 | In hypoxic conditions, GV1001 treatment of cancer cells resulted in decreases of HSP90, HSP70, and HIF-1α. |
| 16 | 24411674 | In addition, significant reduction of Tie2+ CD11b+ monocytes, which were recruited by VEGF from tumor cells and play a critical role in angiogenesis, was observed in GV1001-treated tumors. |
| 17 | 25987009 | Based on in-depth reviews of serological diagnosis of HCC, in addition to AFP, there are other biomarkers: Lens culinaris agglutinin-reactive AFP (AFP-L3), des- carboxyprothrombin (DCP), tyrosine kinase with Ig and eprdermal growth factor (EGF) homology domains 2 (TIE2)-espressing monocytes (TEMs), glypican-3 (GPC3), Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma antigen (SCCA) have been proposed as biomarkers for the early detection of HCC. |